In a finding that may reshape how scientists think about the origins of one of the most common autoimmune diseases in the world, researchers in China have uncovered a detailed molecular portrait of the gut ecosystem in patients with Graves’ disease, revealing a distinctive microbial signature and a pattern of metabolic disruptions that converge on a single, surprising pathway: the way the body processes the dietary amino acid tryptophan. The study, published in BMC Endocrine Disorders, also tackles a long-standing and controversial question in thyroid research by asking whether the notorious stomach bacterium Helicobacter pylori leaves a measurable fingerprint on the gut environment of Graves’ patients.
Graves’ disease is the leading cause of hyperthyroidism worldwide, affecting an estimated 20 to 40 people per 100,000 each year, with incidence continuing to climb. The condition arises when the immune system mistakenly produces antibodies that stimulate the thyroid gland, driving it into a state of hormonal overdrive. The consequences ripple through the entire body, producing the classic constellation of palpitations, weight loss, tremors, diffuse goiter, bulging eyes and a hypermetabolic state that can strain the cardiovascular system. While genetic predisposition clearly plays a role, decades of research have pointed to environmental triggers as essential collaborators in the disease process, though the precise mechanisms remain frustratingly incomplete.
The new research, led by Suna Yang and Xinyue Chang of The Affiliated Yan’an Hospital of Kunming Medical University, together with colleagues including corresponding author Yipeng Wang, took aim at this gap using two of the most powerful analytical tools available to modern microbiome science. The team enrolled 88 patients who had not yet received any treatment for Graves’ disease, along with 33 age- and sex-matched healthy controls. Every participant provided fecal samples, which were subjected to both 16S rDNA sequencing to map the bacterial communities and untargeted liquid chromatography-mass spectrometry to catalogue the thousands of small molecules those communities and the host jointly produce. Crucially, because all patients were treatment-naïve, the researchers could be confident that the observed alterations were not artifacts of antithyroid medication.
The choice to sequence the 16S ribosomal RNA gene reflects standard practice in microbiome research, and the team applied it with rigorous bioinformatic care. After extracting DNA from the stool specimens, they amplified the V3-V4 hypervariable region of the 16S rRNA gene using the universal primers 341F and 805R, then sequenced the libraries on an Illumina NovaSeq platform. The resulting reads were processed through the DADA2 pipeline, which corrects sequencing errors and removes chimeric artifacts to produce amplicon sequence variants with single-nucleotide resolution, a step up from the older operational taxonomic unit approach. Taxonomic classification relied on the SILVA database, and differential abundance testing employed linear discriminant analysis effect size, a three-stage method that combines Kruskal-Wallis and Wilcoxon rank-sum tests with effect-size estimation to pinpoint taxa that reliably distinguish one group from another.
The sequencing results revealed a gut landscape measurably different from that of healthy individuals. At the phylum level, patients with Graves’ disease showed significantly elevated relative abundances of Bacteroidota, Fusobacteriota and Acidobacteriota, while Campylobacterota and Patescibacteria were markedly reduced. Notably, overall alpha diversity, meaning the richness and evenness of species within each individual, did not differ significantly between patients and controls; the change was compositional rather than a general loss of diversity. Among the genera, Bacteroides and Prevotella-9 flourished in the patient group, while Klebsiella, Collinsella and Romboutsia declined. LEfSe analysis reinforced the pattern, identifying the entire Bacteroides lineage from phylum to genus as enriched in Graves’ disease, alongside Prevotella-9, Megamonas and the Lactobacillaceae family.
Each of these shifts carries potential mechanistic weight. Bacteroidota species ferment glucose and lactate into short-chain fatty acids such as succinate, acetate and propionate, molecules with potent immunomodulatory effects. Previous work by Su and colleagues found that although total Bacteroidota rises in Graves’ disease, the key representative species Bacteroides fragilis actually declines, and that its metabolite propionic acid helps regulate the critical balance between regulatory T cells and pro-inflammatory Th17 cells, a balance known to be disturbed in the disease. The elevated Lactobacillaceae observed here is equally suggestive. Some Lactobacillus strains can competitively bind thyroid peroxidase and thyroglobulin antibodies through molecular mimicry, potentially stoking cross-reactive immune responses, and can stimulate gut-resident macrophages to secrete interleukin-6 and interferon-alpha, cytokines linked to Graves’ pathology. Earlier studies have even shown that Lactobacillus abundance correlates positively with thyrotropin receptor antibody titers and falls when patients are treated with methimazole.
The metabolomic arm of the study produced perhaps the most striking results. Using orthogonal partial least squares-discriminant analysis, the researchers demonstrated clear clustering separation between patients and controls, and their screening identified 192 significantly altered metabolic features in positive ion mode alone. Among the most dramatically changed compounds were pregnanetriol and kynurenic acid, both upregulated in patients, while mulberrofuran T and fragransol B were downregulated. Receiver operating characteristic analysis suggested that several of these metabolites could serve as diagnostic markers, with mulberrofuran T achieving an area under the curve of 0.75.
The pathway-level analysis tied these findings together. KEGG enrichment pointed to tryptophan metabolism as a central player, with the metabolites serotonin, kynurenate, xanthurenate and 3-methyldioxyindole all significantly upregulated in Graves’ patients. This is a biologically compelling observation because tryptophan metabolism through the kynurenine pathway generates bioactive molecules that regulate immune responses, neuronal function and intestinal homeostasis. Inflammatory and autoimmune conditions are known to shift tryptophan away from serotonin production and toward kynurenine synthesis, and a 2023 study by Ueland and colleagues independently reported systemic activation of the kynurenine pathway in Graves’ disease, with six of seven elevated serum biomarkers belonging to this pathway. The new fecal data now suggest that this immunological reprogramming has a visible counterpart in the gut lumen, strengthening the case that gut microbes, which are major producers of kynurenine-pathway metabolites, participate in the autoimmune process.
The Helicobacter pylori component of the study addressed a question that has divided the field for over a decade. The gram-negative, microaerophilic bacterium colonizes the gastric epithelium and is best known for causing chronic gastritis, peptic ulcers and gastric cancer, but epidemiological studies have repeatedly linked it to diseases far beyond the stomach, including rosacea, diabetes, immune thrombocytopenic purpura and, in several reports, Graves’ disease. A 2013 study by the same research group had found that gene A-positive H. pylori interacts with human leukocyte antigen II alleles to increase Graves’ risk in the Chinese Han population, raising the possibility that the bacterium contributes to autoimmunity by reshaping the gut environment.
To test this, the team measured H. pylori IgG antibodies in the blood of 61 of the Graves’ patients using enzyme-linked immunosorbent assay, classifying 17 as seropositive and 44 as seronegative. The comparison yielded genuine differences: patients with H. pylori antibodies showed elevated levels of Clostridium sensu stricto 1, Holdemanella and Limosilactobacillus, along with reduced levels of the metabolites N-methyltyramine, N-isovalerylglycine and cafestol. Pathway analysis suggested alterations in arginine and proline metabolism, tyrosine metabolism, primary bile acid biosynthesis and other routes. However, the researchers interpreted these findings with notable restraint. The same microbial changes, they point out, are commonly seen in H. pylori-positive individuals who do not have Graves’ disease, suggesting that the bacterium’s gut effects are not specific to the thyroid disorder. They also caution that serum IgG positivity reflects past exposure rather than necessarily active infection, and that active-infection diagnostics such as the urea breath test would be needed to settle the question definitively.
The authors are transparent about the study’s other limitations as well. As a cross-sectional analysis, it establishes association rather than causation; it cannot determine whether the observed dysbiosis drives the disease or results from the hyperthyroid state itself. Confounders such as body mass index, diet, smoking and iodine intake were not systematically controlled, and the researchers recommend future work incorporating multivariate regression or propensity score matching to disentangle these variables. They also note that because short-chain fatty acids were not directly measured, the hypothesis that altered SCFA profiles mediate the immune effects of Bacteroidota expansion remains to be confirmed through targeted quantitative metabolomics and functional experiments.
Even with these caveats, the study represents a meaningful advance in a field where relatively few microbiome studies have focused specifically on Graves’ disease compared to other autoimmune conditions. The convergence of independent evidence, from this study’s fecal metabolomics to the serum kynurenine findings reported by other groups, paints an increasingly coherent picture in which gut microbes and their metabolic products form a communication channel between the intestinal lumen and the immune system, one that can be corrupted in ways that promote thyroid autoimmunity. If tryptophan metabolism indeed sits at this intersection, it opens a tantalizing therapeutic possibility: interventions that reshape the gut microbiota, or that modulate the kynurenine pathway directly, might one day complement antithyroid drugs in managing the disease. For now, the study stands as a rigorous demonstration that the gut of a Graves’ patient is molecularly distinct, and that the microbes within it may be far more than silent bystanders in the autoimmune storm that attacks the thyroid.
Subject of Research: Gut microbiota and metabolite alterations in treatment-naïve patients with Graves’ disease, including the influence of Helicobacter pylori seropositivity
Subject of Research: Medicine
Article Title: Differential analysis of gut microbiota and metabolites in patients with Graves’ disease and combined Helicobacter pylori infection
Article References: Yang, S., Chang, X., Peng, B., Wei, Y., & Wang, Y. (2026). Differential analysis of gut microbiota and metabolites in patients with Graves’ disease and combined Helicobacter pylori infection. BMC Endocrine Disorders, 26(1), Article 241. https://doi.org/10.1186/s12902-026-02462-0
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02462-0
Keywords: Graves’ disease, Helicobacter pylori, gut microbiota, metabolomics, tryptophan metabolism, 16S rDNA sequencing, autoimmune thyroid disease, kynurenine pathway, Bacteroidota, Lactobacillaceae
Cite Scienmag News
APA MLA Chicago
Morgan Morrow. (September 10, 2026). Gut microbiome and metabolite changes in Graves’ disease with H. pylori infection. Scienmag. https://scienmag.com/gut-microbiome-and-metabolite-changes-in-graves-disease-with-h-pylori-infection/
Morgan Morrow. “Gut microbiome and metabolite changes in Graves’ disease with H. pylori infection.” Scienmag, 10 September 2026, https://scienmag.com/gut-microbiome-and-metabolite-changes-in-graves-disease-with-h-pylori-infection/. Accessed 10 September 2026.
Morgan Morrow. “Gut microbiome and metabolite changes in Graves’ disease with H. pylori infection.” Scienmag. September 10, 2026. https://scienmag.com/gut-microbiome-and-metabolite-changes-in-graves-disease-with-h-pylori-infection/
Copy citation Download RIS
Tags: dietary amino acids and autoimmune disease pathwaysenvironmental triggers influencing autoimmune thyroid disordersenvironmental triggers of Graves’ diseaseGut microbiome alterations in Graves’ diseasegut microbiota and metabolic pathways in Graves’ diseasegut-immunegut-immune-thyroid axisH. pylori infection and immune system modulationH. pylori infection impact on thyroid healthHelicobacter pylori impact on thyroid healthmetabolic disruptions in autoimmune thyroid disordersmicrobial and metabolic biomarkers for Graves’ diseasemicrobial signatures associated with hyperthyroidismmicrobiome and metabolite changes in thyroid autoimmunitymolecular profiling of gut ecosystem in thyroid conditionsmolecular profiling of gut microbiota in Graves’ diseaserole of gut bacteria in autoimmune diseasesrole of Helicobacter pylori in gut immune regulationtryptophan metabolism in autoimmune diseasestryptophan metabolism in Graves’ disease
